Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE).
about
Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transductionEIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV.Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID micePreclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.Ethics of iPSC-based clinical research for age-related macular degeneration: patient-centered risk-benefit analysisGene therapy progress and prospects: Duchenne muscular dystrophy.Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels.Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids.Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.New vectors and strategies for cardiovascular gene therapy.Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genesGeneration of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia AHuman Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivoLentiviral delivery of short hairpin RNAsNeonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.Improved microRNA suppression by WPRE-linked tough decoy microRNA sponges.Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression.Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I.The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis.Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells.Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.
P2860
Q27307010-3C8E5EA8-BA49-48E7-99F4-B5AC40DAA74CQ33237979-F050AAA5-A9A1-4CF3-8930-A62FA451DF86Q33383530-2C2A9001-06E9-4C77-BA98-7F46C3C2505DQ33587590-3C1ECD71-79B2-4269-A589-47120AC08C99Q34082330-F88F8A36-5CE9-4201-A2A4-71BB4AB3C590Q34475775-1ED6FFB3-6FFE-4BC4-8E2D-5C182A827FBBQ34576814-4F37C389-D29D-401D-9838-140781144D96Q34977697-25287C63-0D5F-4F15-8638-291D0F9A1F34Q35853990-F337E6D0-0553-45BC-B6C3-CD7F03E43647Q35874710-3B4A8AC4-8F99-4927-BE1F-E497A85B0334Q36058890-FB18A8C2-BE2B-4F85-A030-15809CA948ECQ36096096-59D76C56-9764-4814-A35C-835C2B00219FQ36174173-8B26A008-5516-490E-ADAA-21C32E288740Q36186475-AD90C1D7-E421-4344-9A18-6CFCE982D67AQ36248825-D69B4F4A-55DC-41C6-AAE5-5988BF9F7C7FQ36385632-0B0760CC-1005-4EA6-A6A3-0C49A46E2039Q36553800-0C49D139-3C26-406C-928C-883938B81CEDQ36939755-5A564DDB-9A36-487B-BCCA-580DA58932B4Q36963968-BC50EDBD-DE71-4F65-976D-6351D742401CQ37430557-E4F59FA3-52DC-4C2D-BA90-08D4068E5620Q39689270-606539B4-75B1-48B2-AE45-66DD218D963AQ39877036-E5BA40DE-A69F-4DBB-B92D-1AE0E3CB6FC8Q40208488-AF3BF346-BB70-4880-B4FF-ECC4BE392811Q40365103-D9381521-FEE0-46DC-81B5-0F4E7845B66CQ40609634-F111E932-1852-4325-B692-4AF7C4D447CDQ41317435-9F786443-BB64-4C42-81C9-1A840D60ACABQ42435326-3DDFC3C9-7CF3-493A-86A8-EF668A35469DQ45422040-FC7F9F38-2FA3-46E7-A6E7-312237037C61Q45855338-2A544B6A-51FE-47B5-96A3-29753EF2F0D0Q45857062-55C88044-3A37-4EB3-B3A5-C8E44556686A
P2860
Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Potential oncogene activity of ...... nal regulatory element (WPRE).
@en
Potential oncogene activity of ...... scriptional regulatory element
@nl
type
label
Potential oncogene activity of ...... nal regulatory element (WPRE).
@en
Potential oncogene activity of ...... scriptional regulatory element
@nl
prefLabel
Potential oncogene activity of ...... nal regulatory element (WPRE).
@en
Potential oncogene activity of ...... scriptional regulatory element
@nl
P2093
P2860
P356
P1433
P1476
Potential oncogene activity of ...... nal regulatory element (WPRE).
@en
P2093
Kingsman SM
Mitrophanous K
P2860
P2888
P356
10.1038/SJ.GT.3302417
P577
2005-01-01T00:00:00Z
P5875
P6179
1014381628